Biomedical subjects

A P Aldenkamp

Publications and source records attributed to A P Aldenkamp.

At least 19 recordsLinked to original sources

PubMed2006

SUDEP in the Netherlands: a retrospective study in a tertiary referral center.

OBJECTIVE: To evaluate risk factors for sudden and unexpected death in epilepsy (SUDEP) in a high-risk population, i.e. patients treated in a Dutch tertiary referral center for epilepsy. METHODS: All patients who died between January 1999 and April 2004 while under treatment of the epilepsy center were identified. Based on clinical data, deaths were classified as definite, probable, possible or non-SUDEP. Potential risk factors were compared in SUDEP cases and non-SUDEP cases. RESULTS: SUDEP incidence was 1.24 per 1000 patient years. SUDEP patients died at a younger age than patients from the control group of non-SUDEP deaths with epilepsy and had an earlier onset of epilepsy. However, the frequently mentioned factors in previous studies, i.e. male sex, generalized tonic-clonic seizures, high seizure frequency, specific AEDs, polytherapy with several AEDs, mental retardation, psychiatric illness and psychotropic comedication, were not found to be correlated with SUDEP. CONCLUSIONS: Even in this high-risk population of patients with refractory epilepsy, treated in a tertiary referral center, SUDEP is not a frequently occurring phenomenon. Specific risk factors could not be identified within an already high-risk population.

Adolescent↗

PubMed2006

Sudden unexpected death in epilepsy patients: Risk factors. A systematic review.

INTRODUCTION: Several risk factors for sudden unexplained death in epilepsy patients (SUDEP) have been proposed, but subsequent work has yielded conflicting data. The relative importance of various risk factors for SUDEP was never explored. The aim of this study is to review systematically risk factors for SUDEP and also to determine their relevance for SUDEP by calculating relative risk factor ratios. METHODS AND MATERIALS: Authors performed a literature-search on "SUDEP" in Medline, the Cochrane Library and EMBASE. Studies with unknown number of SUDEP cases or with less than five SUDEP cases and reviews were excluded from further analysis. The value of each paper was assessed, based on the quality of the study and the reliability of the diagnosis of SUDEP. This value ranged from 1 (low quality) to 10 (high quality). Papers with a value below 7 were eliminated for further analysis. For each analysed factor, a risk factor ratio was determined, with a higher ratio for a stronger risk factor. RESULTS: A number of strong risk factors for SUDEP: young age, early onset of seizures, the presence of generalized tonic clonic seizures, male sex and being in bed. Weak risk factors for SUDEP: prone position, one or more subtherapeutic bloodlevels, being in the bedroom, a strucural brain lesion and sleeping. CONCLUSIONS: In this study, authors have designed a quality scale to select papers. The relative importance of risk factors for SUDEP is demonstrated.

Age Factors↗

PubMed2006

Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures.

The authors investigated the effect of oxcarbazepine on cognitive function in children and adolescents (6 to younger than 17 years of age) with newly diagnosed partial seizures in an open-label comparison with standard antiepileptic drug therapy (carbamazepine and valproate). No differences in cognitive tests were observed between oxcarbazepine and carbamazepine/valproate over a 6-month treatment period.

Adolescent↗

PubMed2006

A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs.

OBJECTIVES: Side-effects of anti-epileptic drugs (AEDs) may be overlooked in patients with epilepsy in everyday clinical practice. The aim of this study was to assess the prevalence and severity of subjective complaints in patients who were considered to be well-controlled and to assess whether these complaints are related to medication, personality traits, or other determinants. METHODS: We included patients with epilepsy who were considered to be well-controlled in a cross-sectional study in seven hospitals in the Netherlands. Their medication had not been changed for six months and an apparent reason to change the medication was lacking at the time of enrolment. Subjective complaints were assessed with a 46-item questionnaire. Using multivariable linear regression modeling, we assessed whether patient characteristics, epilepsy characteristics, medication, quality of life (Qolie-10), and personality traits (SCL-90) explained the presence and severity of complaints. RESULTS: Of 173 included patients, 67% reported moderate to severe subjective complaints on the questionnaire. Cognitive complaints were reported most frequently. Multivariate modeling showed that 61% of the variance in reported complaints could be explained by included determinants. The prevalence and severity of complaints was associated with AED polytherapy and higher scores on psycho neuroticism. CONCLUSIONS: Patients who were considered to be well-controlled proved to report an unexpectedly high number of subjective complaints. Both medication and aspects of personality contributed to the level of complaints. Our study illustrates that subjective side-effects are easily overlooked in everyday clinical practice, possibly because in practice a generally phrased question is used to detect side-effects.

Adolescent↗

PubMed2006

Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy: an open treatment trial.

OBJECTIVE: The purpose of this study was to evaluate the effectiveness and safety of methylphenidate treatment in epilepsy patients with comorbid adult attention deficit hyperactivity disorder (ADHD). METHODS: Six of 156 consecutive patients attending a tertiary epilepsy clinic for diagnostic evaluation of new seizures, 3 patients with epilepsy and 3 patients with psychogenic non-epileptic seizures, were diagnosed with comorbid adult ADHD. These 6 patients entered an open trial of methylphenidate 10 mg twice daily. Clinical improvement was assessed at 6 weeks of follow-up. RESULTS: Both groups showed clinical improvement of ADHD symptoms during treatment. None of the patients with comorbid epilepsy experienced adverse effects on seizure control or antiepileptic drug use. CONCLUSION: In this open trial methylphenidate was safely used in patients with epilepsy and adult ADHD. It was effective against adult ADHD, and there were no adverse effects on seizure severity and frequency. A randomized study is needed to further establish effectiveness and safety.

Adolescent↗

PubMed2005

Vagus nerve stimulation in patients with catastrophic childhood epilepsy, a 2-year follow-up study.

PURPOSE: To establish the long-term efficacy and tolerability of vagus nerve stimulation (VNS) in children with a Lennox-like syndrome. METHOD: This study was a longitudinal observational prospective cohort analysis. Baseline: 6 months. FOLLOW-UP: 24 months. Screening (baseline and every 6 months): MRI (baseline only), EEG, neuropsychological evaluation, ECG and blood sampling for antiepileptic drug levels. Nineteen children are included. RESULTS: A seizure frequency reduction of 20.6% was found at the end of the follow-up period. No relationship was detected between the length of the stimulation period and the reduction in the seizure frequency. 21% of the patients showed a reduction in seizure frequency of 50% or more. The seizure severity showed improvement in the first 12 months of treatment. The largest seizure reduction was found in the patients with highest frequency of background activity at the baseline EEG. Neuropsychological findings: no negative impact on behaviour, moderate improvement in function, behaviour and mood. Largest seizure reduction was found in the group with the highest baseline mental function. The scores for mental age improved independently of the seizure control. Twelve patients (63%) experienced minor side effects, which subsided after 1 month. CONCLUSION: (1) There was a significant reduction in seizure frequency and severity. (2) No serious side effects were recorded. (3) No negative effects on cognition or quality of life were apparent. (4) Patients with highest baseline mental functioning showed the highest seizure reduction. (5) Those patients with less disturbed EEG (high background activity and less interictal epileptic activity) showed the highest seizure reduction.

Adolescent↗

PubMed2005

Complaints associated with the use of antiepileptic drugs: results from a community-based study.

BACKGROUND: Few data exist with respect to the occurrence of chronic side effects due to antiepileptic drugs (AED) in routine clinical practice. OBJECTIVE: To evaluate the prevalence of subjective complaints which patients with epilepsy regard as side effects of their AED treatment in a community-based population. METHODS: Cross-sectional study. Subjects were identified through the database of AED-use in the pharmacies in a suburban area in The Netherlands. Respondents completed a brief questionnaire about their epilepsy, including a checklist with 30 complaints, which are common in AED users. RESULTS: We present data of 346 responding adults with treated epilepsy from a population of 107,000 adult inhabitants. Eighty percent was using monotherapy, with few patients taking new AEDs. Almost 60% of the patients reported complaints probably due to side effects in at least three domains. General CNS-related side effects were reported most often; memory problems (21.4% of the patients) and fatigue (20.3%) were dominant. Polytherapy was associated with more side effects than monotherapy. We identified differences in profiles of complaints between valproate, carbamazepine and phenytoin monotherapy. Complaints were not substantially associated with ongoing seizures or other treatment factors. CONCLUSIONS: The majority of patients taking AEDs for epilepsy think they have side effects form their drugs, even when seizures were in remission and when monotherapy was used. Our findings suggest a need to improve monitoring of complaints of side effects of AEDs and to explore the feasibility of interventions aimed at reduction of such complaints in everyday clinical practice.

Adolescent↗

PubMed2005

Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.

Mood-modulating profiles of antiepileptic drugs (AEDs) have been classified by Ketter, Post, and Theodore [Neurology 1999; 53 (5, Suppl. 2) S53-76] into two classes: the first class is assumed to have deactivating effects related to GABA potentiation, and the second class is assumed to have activating effects that are associated with glutamate attenuation. We tested this hypothesis by reviewing the multiple mechanisms of action of topiramate (TPM) and levetiracetam (LEV) together with clinical behavioral side effects of patients who had been treated with TPM and LEV in a tertiary referral center for epilepsy. We found LEV to manifest activating and deactivating side effects equally and TPM to act as a deactivating AED, with tiredness/sleepiness side effects being predominant. TPM, in comparison to LEV, was found to be associated with a high incidence of side effects. Testing the hypothesis of Ketter et al. (1999) the deactivating effects of TPM may be coupled to a predominance of potentiation of GABA, but the oversimplified basis of the model needs to be acknowledged.

Adult↗

PubMed2005

Effect of epilepsy on psychomotor function in children with uncomplicated epilepsy.

This study assessed the impact of epilepsy on motor function in children. We aimed to analyze the effect in uncomplicated epilepsies (cryptogenic partial and idiopathic generalized epilepsy). A group of 87 children with epilepsy (47 males, 40 females; mean age 8y, standard deviation [SD] ly 9mo, range 4y 11mo to 12y 11mo), but without learning disability* or other neurological comorbid disorders, was compared with a control group of 107 children (76 males, 31 females; mean age 8y 4mo, SD 2y 2mo, range 4y 7mo to 12y 2mo). The differences in main motor skills and psychomotor speed were analyzed using the Movement ABC and computerized measures for simple reaction times and finger tapping. No significant difference in motor function was found. The overall psychomotor development of children with epilepsy is comparable to controls. However, a significant slowing of psychomotor speed in the group with epilepsy was reported. No relation with antiepileptic drug treatment was demonstrated and no difference in psychomotor speed between different types of epilepsy was found. The existence of a condition leading to excessive neuronal discharge leads to a general cortical inhibition. The slowing of psychomotor speed in children with uncomplicated epilepsy may be the behavioural presentation of this inhibition.

Child↗

PubMed2005

Behaviour, cognition and epilepsy.

Cognitive and behavioural impairments have been observed as a consequence even of single seizures. In individuals with high seizure frequency, such impairments may accumulate and have a much greater impact on daily life than hitherto suspected. In addition, the risk of behavioural impairments is increased for some seizure types, such as secondary generalized seizures. Moreover, for all epilepsy types, increased risk is associated with persistent or poorly controlled seizures. Clinical studies show that cognitive impairments induced by seizures are reversible for most seizure types when seizures are controlled adequately. Additionally, for some seizure types there may be a kind of time window within which impairments are reversible. Exceeding the time window may result in irreversible impairment. These studies suggest that antiepileptic drug treatment can thus protect against such secondary behavioural impairments or at least correct these when seizures are controlled. This emphasizes the need to achieve complete and early seizure control. On the contrary, all antiepileptic drugs have a detrimental effect on the central nervous system and may affect cognitive function, behaviour and mood to some extent. Some treatments may undo the beneficial effects of antiepileptic drug treatment by inducing new or other cognitive impairments. This once more illustrates the need for the emphasis of clinical practice to evolve from mere seizure control to a more comprehensive approach, in which the prevention of central cognitive effects and effects on daily life of both seizures and drugs is given due attention. Optimal management requires a careful balance between, on the one hand, the desire to reach early and maximal seizure control and, on the other, the need to avoid tolerability problems related to cognitive and behavioural impairments. This article reviews how this balance can be achieved for older and newer antiepileptic drugs.

Affect↗

PubMed2004

Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.

For the treatment of patients with chronic refractory epilepsies, information about the long-term efficacy and safety profile of any new antiepileptic drug is crucial. Topiramate has been proven to be effective in patients with refractory chronic partial epilepsies in short-term controlled clinical trials, but the long-term retention, long-term efficacy, and long-term side-effect profile have not been sufficiently investigated. We analyzed all patients who had been treated with topiramate in the Epilepsy Centre Kempenhaeghe from the introduction of the drug in the spring of 1993 up to a final assessment point in mid-2002. In total, 470 patients were identified. The data show that the clinical dose achieved was about 200mg/day, reached after approximately 6 months of treatment. Further dose escalation in the survivors was slow, with a mean dose of about 300 mg/day after 24 months of treatment. Mean titration dose is 25mg/week, but titration strategy is mostly individual and responds to patient complaints. With respect to seizure frequency, 10-15% of the patients were seizure-free at the 6-month evaluation; 4 patients achieved a 2-year remission. Retention rate was 53% after 1 year, 45% after 2 years, 38% after 3 years, and 30% after 4 years. At 4 years, almost 70% of the patients had discontinued topiramate. The main reason was adverse events, which accounted for about 65% of the discontinuations. Behavioral side effects were dominant, with mental slowing (27.6%), dysphasia (16.0%), and mood problems (agitation: 11.9%) being the most frequently reported side effects. In about 10% of the patients side effects led to discontinuation despite the obvious favorable effects on seizure frequency. Comparisons between the patients who discontinued topiramate treatment and those who continued topiramate showed that discontinuation was associated with comedication (vigabatrin and lamotrigine). Our conclusion is that TPM is associated with a high incidence of side effects in clinical practice, affecting long-term retention. Meaningful prognostic factors that may help us in clinical decision making, i.e., to prevent the side effects or to help us identify those at risk, have not been found.

Adolescent↗

PubMed2004

The cognitive impact of epileptiform EEG-discharges; relationship with type of cognitive task.

In this study we analyzed the effect of differing task dimensions (high vs. low information demand; short vs. long testing duration) on the occurrence of epileptiform EEG-discharges and the cognitive impact of such discharges. We performed this study only in patients with focal discharges as this appears to be the most complicated group to assess any relationship between epileptiform EEG-discharges and cognitive impairment. Seventeen patients with focal discharges in the EEG and an established diagnosis of localization-related (partial) epilepsy were included. The following tasks were used: Low information demand: auditory and visual RT; high information demand: BCRT and CVST. Short testing duration: Arithmetic and Reading; long testing duration: Vocabulary and Block Design. The percentage of patients with epileptiform EEG-discharge and EEG-related cognitive impact were compared using Chi-square testing. The occurrence of epileptiform EEG-discharges was not associated with one of the experimental conditions introduced in our study, that is, high/low information demand or short/long testing period. Also the difference between computerized reaction-time measurement and more traditional 'paper and pencil tasks' such as reading was not statistically significant. The only statistical significant difference was the more frequent occurrence of epileptiform EEG-discharges during tasks that used the visual input mode. In addition, we could identify one test that appeared to be particularly sensitive to direct cognitive effects of epileptiform EEG-discharges. Only for the CVST, the computerized visual searching task, the relationship with epilepsy-related cognitive impact is statistically significant. This test is the most mentally demanding test of the tests presented in our study and measures speed of visual information processing, using complex stimulus patterns and has a long testing duration. Our results do not confirm that any of the investigated task dimensions (high vs. low information demand; short vs. long testing duration) have a dominant effect on the occurrence of epileptiform EEG-discharges and the cognitive impact of such discharges. The effect found for the CVST suggest that three factors combined are necessary to assess the impact of epileptiform EEG-discharges on cognition: visual input mode, longer testing duration and high information processing demand.

Auditory Perception↗

PubMed2004

Relationships between epilepsy-related factors and memory impairment.

OBJECTIVES: In this study, we will explore the effect of epilepsy-related factors such as: 'type of epilepsy, 'site and side of focus localisation' and 'age at onset', as well as four seizure-related factors: 'years with continuing seizures', 'seizure type' and 'seizure frequency', and the treatment factor 'adverse effects of the medication', on memory impairment. Additionally, we explored whether these epilepsy factors are related to different aspects of memory, i.e. short-term recall vs long-term recall, learning, and verbal memory vs non-verbal memory. MATERIAL AND METHODS: A total of 252 patients with epilepsy and subjective memory complaints were consecutively included from the three epilepsy centres in the Netherlands. To assess memory functions the Wechsler Memory Scale-Revised (WMS-r), and the Dutch version of the California Verbal Learning Test for verbal list learning, was administered. RESULTS: A multivariate analysis of variance (MANOVA) did not show statistically significant effects of the epilepsy factors on memory for the total study sample. For the patients with a unilateral epileptogenic focus in the temporal lobes, MANOVA showed statistically significant effects of lateralisation, with most impairment for patients with left temporal lobe epilepsy and, independently, seizure frequency and 'years with seizures'. CONCLUSION: We may conclude that epilepsy-related dysfunctions in the temporal lobe are the dominant risk factor for developing memory problems, specifically verbal memory problems (verbal learning and problems consolidating verbal information), with more severe impairments with continuing seizures and when seizure frequency is high.

Adolescent↗

PubMed2003

Treatment of epilepsy in general hospitals: do patients and neurologists agree on success or failure?

OBJECTIVE: Opinions of patients and neurologists about aspects of their epilepsy and their treatment were compared. METHOD: Thirty-two neurologists, working in general hospitals, included 198 patients aged 16 years or more. Both neurologist and patient independently completed a questionnaire consisting of simple open questions about the epilepsy and the drug treatment. The average characteristics for this group are very similar to characteristics of the general population: age and gender distribution, highest completed educational level, occupational participation and family circumstances are not statistically significant from the general population. RESULTS: Neurologists and patients appear to agree about most areas that we assessed: seizure count, severity of epilepsy, efficacy and tolerability of the treatment and impact of the epilepsy and treatment on daily life (as expressed in the 'Quality of Life ratings'). Detailed analysis showed that this agreement is partly artificially increased by the group with good outcome and less strong or even absent for the more severe epilepsies. For seizure count, we see 96.4% agreement for the group with low seizure frequency and 73.1% agreement in case of high seizure frequency. For the evaluation of severity of the epilepsy, 73.2% agreement is found for mild classification and 16.6% agreement for the severe classification. Agreement on Quality of Life (QOL) is almost complete in patients with excellent QOL (91% agreement) and almost absent for a low QOL (17% agreement). Finally, the same pattern is found for reports on side-effects of the medication. Both neurologists and patients report side-effects in about 40% of the cases. This suggests excellent agreement but individual data show that agreement is only satisfactory for the milder epilepsies (16.2% vs. 16.2%). For the more severe agreement is almost absent (4.1% of the neurologists vs. 13.4% of the patients). DISCUSSION: Possibly, it is more difficult for the neurologist to perceive and appraise all relevant factors in the case of complex epilepsies. Alternatively, subjective definitions and assumptions of patients differ from the standards set by the neurologists in the case of continuing seizures. The clinical relevance of our findings is that, especially in the cases of more severe and refractory epilepsies, patients' opinions are of utmost importance and we cannot take our own opinions and evaluations at face value.

Adolescent↗

PubMed2003

Psychosocial reactions to the epilepsy in an unselected group of patients with epilepsy under treatment in general hospitals.

OBJECTIVE: This study aimed at exploring the psychosocial reactions to epilepsy in a group of patients with uncomplicated well-controlled epilepsy. METHOD: One hundred and ninety-eight patients, referred by neurologists in a general hospital completed a questionnaire, consisting of simple open questions about the epilepsy and the drug treatment. Additionally, the patients were asked to complete the QOLIE-10-scale as well as a short questionnaire with questions about attitudes towards epilepsy and the treatment. RESULTS: The overall psychosocial outcome was favourable in our study sample. About 50% of the patients have a paid job, have an average educational level and the majority (almost 70%) of the patients have a partner. This is not different from findings in the general population. In line with these social findings, the patients report in majority that the epilepsy is well integrated: as a rule the family and friend are informed and they feel that the epilepsy is accepted in society. Restrictions are limited to activities such as swimming. Consequently, quality of life (QOL) is high for the majority of the patients, with only 6% of the patients reporting a low QOL. DISCUSSION: It is often claimed that people with epilepsy, as a group, have more psychosocial problems than control populations of healthy subjects. As this may be true for the average comparisons between patients with epilepsy and controls, we must take into account during clinical practice that these problems occur predominantly in the minority of patients with refractory epilepsy. Patients with well-controlled epilepsy do not show worrying reactions to the epilepsy.

Adaptation, Psychological↗

PubMed2003

Usefulness of language and memory testing during intracarotid amobarbital testing: observations from an fMRI study.

BACKGROUND: Several procedures for testing language lateralization and memory function exist during the intracarotid amobarbital test (IAT). The use of functional magnetic resonance imaging (fMRI) gives the opportunity to assess the validity of some of these procedures, or at least to inspect the neuronal correlates. A comprehensive fMRI protocol was tested, aimed at addressing aspects of lateralization of language, as well as testing memory in relation to activation of mesiotemporal regions. Here we report observations with possible consequences for the current IAT procedures. MATERIALS AND METHODS: The protocol consisted of three language tasks (overt naming, semantic decision and silent word generation) and two memory tasks (encoding and retrieving visual scenes). The paradigms used a block-related procedure in nine right-handed normal volunteers. During the procedure dynamic weighted full brain images were acquired which are sensitive to the blood oxygenation activation effect. RESULTS: Encoding showed symmetrical bilateral activation in the mesiotemporal regions, specifically the hippocampus, parahippocampal gyrus and fusiform gyrus. With a retrieval task activation of the mesiotemporal areas was restricted to the posterior hippocampal area. Overt object naming showed results, similar to encoding tasks with bilateral activation of hippocampal areas. Silent word generation showed much stronger ability to lateralize than the other two language-related tasks and especially object naming. CONCLUSION: Activation revealed by fMRI activation shows that IAT procedures, using active semantic language processing or comprehensive procedures with multiple language tasks have the highest guarantee for individual activation lateralization. Simple object naming does not guarantee a lateralized language fMRI activation pattern. Of the different memory procedures during IAT, the procedures (Interview and the Montreal) demanding encoding processing will be related to larger areas of bilateral hippocampal activation than procedures (Seattle) exclusively requiring retrieval. Moreover, tasks using recognition of previously presented language items (naming objects) are equally effective for assessing hippocampal activation compared with presenting separate memory items.

Adult↗

PubMed2002

Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.

PURPOSE: This study aimed at investigating the cognitive and mood effects of lamotrigine (LTG) versus valproate (VPA) and placebo (PBO). METHODS: By studying the effects in healthy volunteers, it is possible to separate the genuine effects of LTG from the cognitive improvements, caused by better seizure control. The study used a pretest-posttest comparison of 50 mg LTG, 900 mg VPA, or PBO in a double-blind single-dummy parallel-group design with 30 healthy volunteers. Study duration was 12 days (with a last control on day 13). Outcome measures included cognitive tests (FePsy neuropsychological test battery), mood scales (ASL; mood-rating scale), and a scale for subjective complaints (ABNAS Neurotoxicity scale). Total sleep time was controlled with actigraphic recordings. The results were analyzed by comparing the change over time (pretest with posttest) for the three treatments with Student's t tests. RESULTS: COGNITIVE TESTS: significant differences between the treatments were found for measurements of cognitive activation (i.e., three of the four simple reaction-time measurements showed statistically significant differences in change between PBO and LTG in favor of LTG (p=0.03; 0.03; 0.04); two of four tests showed statistically significant differences in change between LTG and VPA, both in favor of LTG (p=0.03; 0.05). SUBJECTIVE COMPLAINTS: the ABNAS-neurotoxicity scale reveals a significant reduction of drug-related cognitive complaints for the subjects taking LTG, relative to VPA (p=0.02). MOOD RATING: significant changes were found on the scale assessing "tiredness," showing increased tiredness/sedation for VPA relative to PBO (p=0.02) and on the "timid scale" for LTG reporting "being more at ease" compared with both PBO and VPA (p=0.02; 0.02). The general direction of change for the mood scales was toward "activation" for LTG (five of six scales improved), whereas for VPA, the reverse effect was found (four of six scales showed a change in the direction of "tiredness/sedation"). CONCLUSIONS: Short-term treatment in normal volunteers with a low dose of LTG resulted in improved cognitive activation on simple reaction-time measurements, a more positive subjective report about the impact of drug treatment relative to VPA, and mood changes concurring with the activating effect demonstrated by the cognitive tests.

Adult↗

PubMed2002

The A-B neuropsychological assessment schedule (ABNAS): the relationship between patient-perceived drug related cognitive impairment and results of neuropsychological tests.

Our intention was to evaluate the relationships between the A-B neuropsychological assessment schedule (ABNAS) as a measure of patient-perceived cognitive effects of antiepileptic drugs (AEDs) and the results of neuropsychological tests. The measure was developed specifically to assess patient-perceived cognitive effects of AED treatment. Evidence of its reliability and validity has been previously documented. In this study 96 patients were included using stratified inclusion-criteria to guarantee variability of performance: 55 patients were included from a 'low risk condition' with respect to possible cognitive effect (i.e. monotherapy carbamazepine within a dose range of 600-1200 mg/day) and 41 patients were included from a 'high risk condition' (i.e. polytherapy of three or two AEDs including either phenytoin, phenobarbitone or a benzodiazepine; treatment with topiramate with a titration speed using 50 mg or higher increments per week and within the first 6 months of treatment). All patients were prospectively assessed using the ABNAS and five neuropsychological tests (all part of the FePsy test system) with proven sensitivity of cognitive effects of antiepileptics: three tasks using reaction-time to measure speed ('simple (visual) reaction-time measurement', 'the binary choice reaction test' and 'the computerized visual searching task'); one test measuring motor speed ('the finger tapping task'); and a memory test ('recognition of words'). The three reaction-time tasks and the finger tapping test were significantly correlated with the ABNAS-score with correlations ranging from 0.22 to 0.35. The highest correlation was with 'simple (visual) reaction-time measurement' (0.35). Discriminant analysis showed that with the neuropsychological tests 61.5% of the patients were correctly identified as having high/low ABNAS-scores. The ABNAS underestimated impairment in 17.8% of the patients ( = low ABNAS-score but impairment on the neuropsychological tests). The present study contributes to the already existing evidence of validity of the ABNAS as a screening instrument for clinical practice as the relationship between the ABNAS-score and results of neuropsychological tests can help to identify who is at risk and needs further referral for neuropsychological assessment. Moreover the correlation between ABNAS-score and those neuropsychological tests that are sensitive for drug-effects may provide a sensitive instrument in early drug-development phases while keeping the burden on financial and time resources to a minimum.

Adult↗